Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Short Communication
Experience with Aerosolized Imipenem in Patients with Cystic Fibrosis and Achromobacter xylosoxidans
Maria Celeste Marcos*, Emma Vazquez Espinosa, Layla Diab Caceres, Tamara Alonso Perez, Ana Martínez Meca, Carolina Cisneros Serrano and Rosa M Giron Moreno
Department of Pulmonology, La Princesa Institute for Health Research, Hospital Universitario de La Princesa, Madrid, Spain
- *Corresponding Author:
- María Celeste Marcos
Pulmonology Department, La Princesa Institute for Health Research
Hospital Universitario de La Princesa, c/Diego de León 62, 28006, Madrid, Spain
Tel: +34 91 5202277
E-mail: cele141082@hotmail.com
Received date: September 10, 2017; Accepted date: September 21, 2017; Published date: September 25, 2017
Citation: Marcos MC, Espinosa EV, Cáceres LD, Pérez TA, Meca AM, et al. (2017) Experience with Aerosolized Imipenem in Patients with Cystic Fibrosis and Achromobacter xylosoxidans. J Infect Dis Ther 5:335. doi: 10.4172/2332-0877.1000335
Copyright: © 2017 Marcos MC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Achromobacter xylosoxidans is a gram negative non-fermentative rod that infects adult cystic fibrosis patients with moderate to severe lung compromise. Its clinical implications are still to be determined. The aim of this study was to analyze the impact of inhaled imipenem on forced expired volume in 1 sec (FEV1) and number of exacerbations in adult cystic fibrosis patients. Patients colonized by A. xylosoxidans with more than two intravenous antibiotic cycles and/or ≥ 5% FEV1 impairment during the last year were included.
We included six patients with a mean age of 24.8 years. At the beginning of treatment FEV1 was 1.18 l (52%) with a mean of 3.4 exacerbations in the previous 12 months and 2.24 (p=0.04) the following 12 months. There was a significant difference between the initial FEV1 value and three months after treatment (p=0.005).
